

# PBE

As of June 30, 2010

## Fund Description

The PowerShares Dynamic Biotechnology & Genome Portfolio is based on the Dynamic Biotechnology & Genome Intellidex. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex thoroughly evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Underlying Intellidex is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. Concentrated industry investments involve greater risks than more diversified investments.

## Fund Data<sup>3</sup>

Dynamic Biotechnology & Genome Portfolio PBE  
Intraday NAV (IIV) PBE.IV

## Underlying Index Data

Dynamic Biotechnology & Genome Intellidex DZO  
Index Provider NYSE Arca

## 5-Year Alpha, Beta and Correlation<sup>1,3</sup>

Data shown are that of the underlying Index relative to each respective benchmark index.

	Alpha	Beta	Correlation
S&P SuperComposite			
Biotech	1.58	0.70	0.50
S&P 500	4.82	0.91	0.53

## Fund Inception: June 23, 2005


<sup>1</sup> Index returns do not represent Fund returns. An investor cannot invest directly in an index.

<sup>2</sup> Returns for the benchmark indexes are based on the closest month end to the Fund's inception date.

Neither the underlying Index nor the benchmark indexes charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown; nor do any of the indexes lend securities, and no revenues from

# PowerShares Dynamic Biotechnology & Genome Portfolio

## Growth of \$10,000<sup>1</sup>



## Fund Performance & Index History (%)<sup>1</sup>

	1 Year	3 Year	5 Year	10 Year	Fund Inception <sup>2</sup>
<b>Underlying Index</b>					
Dynamic Biotech & Genome Intellidex	26.04	-1.06	3.41	-	3.74
<b>Benchmark Indexes</b>					
S&P SuperComposite Biotech	-5.75	-2.50	2.49	-	2.49
S&P 500	14.43	-9.80	-0.79	-	-0.79
<b>Fund</b>					
NAV	24.04	-1.83	3.01	-	3.33
After Tax Held	23.84	-1.89	2.98	-	3.30
After Tax Sold	15.62	-1.58	2.56	-	2.84
Market Price	24.02	-1.76	3.04	-	3.33

Performance data quoted represents past performance. As stated in the Fund's prospectus, the gross annual fund operating expense ratio is 0.62%. However, the Adviser has contractually agreed to waive fees and/or pay certain Fund expenses which resulted in a lower fee actually paid by investors. The expenses borne by the Adviser are subject to recapture by the Adviser for up to three years from the date the fee or expense was borne by the Adviser. These waivers and reimbursement contracts extend through at least Aug. 30, 2010. Past performance is not a guarantee of future results; current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and Shares, when redeemed, may be worth more or less than their original cost. The Shares' performance reflects fee waivers, absent which performance would have been lower. See [invescopowershares.com](http://invescopowershares.com) to find the most recent month-end performance numbers. After Tax Held represents total return after taxes on distributions and assumes Shares have not been sold. After Tax Sold represents total return after taxes on distributions and the sale of Fund Shares. After-tax returns reflect the highest federal income tax rate but exclude state and local taxes. Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times.

## 5-Year Index Statistics<sup>1,3</sup>

	Performance (%)	Volatility (%)	Sharpe Ratio
Dynamic Biotechnology & Genome Intellidex	3.41	20.91	0.05
S&P SuperComposite Biotech	2.49	21.10	0.00
S&P 500	-0.79	16.81	-0.19

securities lending were added to the performance shown. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in the Fund.

The S&P SuperComposite Biotech Index consists of all biotechnology stocks included in the S&P SuperComposite 1500 Index. The S&P 500<sup>®</sup> Index is an unmanaged index considered representative of the U.S. stock market.

**Shares are not FDIC insured, may lose value and have no bank guarantee.**


**Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 50,000 Shares.**



# PowerShares Dynamic Biotechnology & Genome Portfolio

As of June 30, 2010

Top 30 Fund Holdings (%) <sup>4</sup>	
Name	Weight
Genzyme Corp.	5.27
Illumina Inc.	5.23
Amgen Inc.	5.13
Biogen Idec Inc.	5.06
Gilead Sciences Inc.	4.82
Waters Corp.	4.78
Life Technologies Corp.	4.77
Sigma-Aldrich Corp.	4.73
Abraxis BioScience Inc.	4.60
Talecris Biotherapeutics Holdings Corp.	3.51
Rigel Pharmaceuticals Inc.	3.04
Alkermes Inc.	3.02
Alexion Pharmaceuticals Inc.	2.82
Neogen Corp.	2.79
Enzon Pharmaceuticals Inc.	2.74
Nektar Therapeutics	2.73
Theravance Inc.	2.73
Cubist Pharmaceuticals Inc.	2.64
Bruker Corp.	2.63
United Therapeutics Corp.	2.63
Geron Corp.	2.62
Techne Corp.	2.62
Dionex Corp.	2.61
Pharmasset Inc.	2.56
ViroPharma Inc.	2.54
Affymetrix Inc.	2.48
Inspire Pharmaceuticals Inc.	2.42
Incyte Corp.	2.37
Myriad Genetics Inc.	2.26
Exelixis Inc.	1.85



**Fund Details<sup>3</sup>**

Weighted Harmonic Average Stock Price-to-Earnings Ratio	17.68
Weighted Harmonic Average Stock Price-to-Book-Value Ratio	2.98
Weighted Average Return on Equity	9.87
Weighted Market Cap (mm)	7,610
Approximate Number of Securities	30
Expense Cap <sup>5</sup>	0.60%
CUSIP	73935X856
Listing Exchange	NYSE Arca

**Fund Sector Allocations (%)**

Consumer Discretionary	-
Consumer Staples	-
Energy	-
Financials	-
Health Care	95.27
Industrials	-
Information Technology	-
Materials	4.73
Telecommunication Services	-
Utilities	-

**Annual Index Performance (%)**

	Biotech Intellidex	S&P Biotech
2006	1.38	-1.92
2007	5.66	-2.60
2008	-25.68	10.57
2009	23.06	-5.35
2010 YTD	4.13	-9.78

**Fund Market-Cap Allocations (%)**

Large-Cap Growth	10.46
Large-Cap Value	10.56
Mid-Cap Growth	33.64
Mid-Cap Value	-
Small-Cap Growth	45.33
Small-Cap Value	-

**Fund Subindustry Allocations (%)**

Biotechnology	59.67
Health Care Supplies	2.79
Life Sciences Tools & Services	25.12
Pharmaceuticals	7.69
Specialty Chemicals	4.73

## Leading the Intelligent ETF Revolution®

Underlying Index performance does not represent Fund performance.

<sup>3</sup> The Intraday NAV is a symbol representing estimated fair value based on the most recent intraday price of underlying assets.

Volatility is the annualized standard deviation of index returns.

Beta is a measure of relative risk and the slope of regression.

Sharpe Ratio is a risk-adjusted measure calculated using standard deviation and excess return to determine reward per unit of risk. A higher Sharpe Ratio indicates better risk-adjusted performance.

Correlation indicates the degree to which two investments have historically moved in the same direction and magnitude.

Alpha is a measure of performance on a risk-adjusted basis.

Stock Price-to-Earnings Ratio is the share price divided by earnings per share. It is measured on a 12-month trailing basis.

Stock Price-to-Book-Value Ratio is the ratio of a stock's market price to a company's net asset value.

Weighted Harmonic Average is a method of calculating an average value that lessens the impact of large outliers and increases the impact of small ones.

Weighted Average Return on Equity is net income divided by net worth.

Weighted Market Capitalization is the sum of each underlying securities' market value.

<sup>4</sup> Please see the website for complete holdings information. Holdings are subject to change.

<sup>5</sup> The weighted costs excluded from the expense cap include: legal fees pertaining to the Fund's shares offered for sale, SEC and state registration fees, initial fees paid to be listed on an exchange and sublicensing fees. The expense cap is not representative of the total expenses the investor may pay. Please refer to the prospectus for a complete fee schedule.

The Fund contains securities in the biotechnology and genome industry, and the pharmaceuticals industry. Companies engaged in these industries are subject to greater risks, and are more greatly impacted by market volatility, than more diversified investments.

Investing in securities of small and medium-sized companies may involve greater risk than is customarily associated with investing in large companies.

The Fund is considered non-diversified and may be subject to greater risks than a diversified fund.

PowerShares® is a registered trademark of Invesco PowerShares Capital Management LLC. The Intellidex™ Indexes are trademarks of NYSE

Euronext or its affiliates and are licensed for use by Invesco PowerShares Capital Management LLC in connection with the PowerShares Intellidex investment products. The products are not sponsored or endorsed by NYSE Arca, and NYSE Arca makes no warranty or representation as to the accuracy and/or completeness of the Indexes or results to be obtained by any person from use of the Indexes or the trading of the products.

**Invesco Distributors, Inc. is the distributor of the PowerShares Exchange-Traded Fund Trust.**

**Invesco PowerShares Capital Management LLC and Invesco Distributors, Inc. are indirect, wholly owned subsidiaries of Invesco Ltd.**

**An investor should consider the Fund's investment objective, risks, charges and expenses carefully before investing. For this and more complete information about the Fund call 800 983 0903 or visit [invescopowershares.com](http://invescopowershares.com) for a prospectus. Please read the prospectus carefully before investing.**

Note: Not all products available through all firms.